Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569355 | 0.86 | GAA (0.38) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL14904840 | 0.80 | CTSL (0.43) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL12709302 | 0.78 | GAA (0.34) | GAAMEN1KMT2AMAPK1HCRTR2 | |
| SCHEMBL25320175 | 0.78 | GAA (0.35) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL21184066 | 0.78 | MEN1 (0.51) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL31049041 | 0.78 | MEN1 (0.47) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL5554379 | 0.77 | MEN1 (0.37) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL17627172 | 0.76 | MEN1 (0.54) | GAAMEN1KMT2ACTSLMAPK1 | |
| SCHEMBL21398708 | 0.75 | CTSL (0.36) | MEN1KMT2ACTSLMAPK1BTK | |
| SCHEMBL2947606 | 0.75 | GAA (0.34) | GAAMEN1KMT2AMAPK1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570617-B2 | Use of triazole compound as ghrelin receptor agonist | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-10 | — | — | US | disclosed |
| US-12398109-B2 | 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-08-26 | — | — | US | disclosed |
| CN-120081796-A | Use of triazole compounds as gastric somatostatin receptor agonists | 庆北大学校产学协力团 | 2025-06-03 | — | — | CN | disclosed |
| CN-116669575-B | Use of triazole compounds as gastric somatostatin receptor agonists | 庆北大学校产学协力团 | 2025-04-04 | — | — | CN | disclosed |
| EP-3789380-B1 | 2-AMINO-2-(1,2,3-TRIAZOLE-4-YL)PROPANE-1,3-DIOL DERIVATIVE OF NOVEL COMPOUND FOR DIRECTLY INHIBITING ASM ACTIVITY, AND USE THEREOF | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2024-12-04 | — | — | EP | disclosed |
| CN-118234492-A | Pharmaceutical composition for preventing or treating alopecia areata with function of functional inhibitor for S1PR1 and S1PR4 | 次代生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-20240148698-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-05-09 | — | — | US | disclosed |
| CN-112351974-B | Novel compound 2-amino-2- (1, 2, 3-triazole-4-yl) -1, 3-propanediol derivative capable of directly inhibiting ASM activity and application thereof | 庆北大学校产学协力团 | 2024-01-26 | — | — | CN | disclosed |
| CN-117396199-A | Pharmaceutical composition for preventing or treating inflammatory bowel disease as a functional antagonist of S1PR1 and S1PR4 | 次代生物科学株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023224362-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RADIATION-INDUCED PULMONARY FIBROSIS, ACTING AS FUNCTIONAL ANTAGONIST OF S1PR1 AND S1PR4 | 주식회사 넥스트젠바이오사이언스 | 2023-11-23 | — | — | WO | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| CN-101730677-A | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2010-06-09 | — | — | CN | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | GAA 3585/4885MEN1 2056/4885KMT2A 1823/4885 |
| US-20240148698-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | S1PR5, S1PR4, S1PR1 | GAA 3652/4885MEN1 2458/4885KMT2A 2102/4885 |
| US-12570617-B2 | Use of triazole compound as ghrelin receptor agonist | GIPR, GLP1R, GCGR | GAA 3251/4885MEN1 4557/4885KMT2A 3894/4885 |
| US-12398109-B2 | 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof | CHRNB2, ACHE, SMPD2 | GAA 409/4885MEN1 3762/4885KMT2A 2205/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | GAA 1918/4885MEN1 1026/4885KMT2A 525/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | GAA 4315/4885MEN1 525/4885KMT2A 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.